STICHTING HEALTH ACTION INTERNATIONAL [ Stichting HAI ]

Overtoom 1054 HK Amsterdam - Netherlands

Involved in the following projects during the 3rd programme

3rd Health Programme (2014-2020)
Health Action International (HAI) Europe Multi-annual Programme 2015-2017: Equitable access to medicines, their rational use and good governance in the European Union [HAI_FY2015]
HAI Europe contributes to European Union (EU) policy that promotes universal and equitable access to affordable needed medicines of assured quality and policy and practice that ensures those medicines...
HAI Europe contributes to European Union (EU) policy that promotes universal and equitable access to affordable needed medicines of assured quality and policy and practice that ensures those medicines are used rationally. HAI Europe’s work plan 2015-2017 is dedicated to identify, monitor and support EU policies that provide a response to persistent shortfalls in access to medicines and that are aligned with HAI’s overarching goals on Access to Needed Medicines, Rational Use of Medicines and Democratisation of Medicines Policy in Europe. HAI will work towards these goals through research, evidence-based policy analysis and intervention, training and information sharing. As a result, HAI will advocate for citizen-centred public health policies that address health challenges in the EU and health inequity both within and between EU member states. HAI Europe’s multi-annual programme addresses the objectives of the Third Health Programme and contributes to EU added-value by supporting medicines policies that have the potential to maximise the impact of policy intervention at a regional level, and thereby contributes to better and safer healthcare for EU citizens. HAI Europe is a non-profit, independent NGO and maintains a membership network of consumers, healthcare providers, academics and public interest groups working on pharmaceutical policy issues in Europe. The growing European regional network is represented in over half of EU Member States. The HAI Europe office coordinates actions with the HAI Europe Members Association, and integrates its work in collaboration with other European civil society organisations.
Start date: 01/01/2015 - End date: 31/12/2015

Call: Specific Grant Agreements for 2015 under the Framework Partnership Agreement for Operating Grants 2015-2017
Topic: Financial contribution to the functioning of non-governmental body (Specific Grant Agreement 2015)
3rd Health Programme (2014-2020)
HAI_FY2016 [HAI_FY2016]
Health Action International’s (HAI) work in Europe aims at contributing to EU policy that promotes universal and equitable access to affordable medicines for needed treatment. HAI also supports poli...
Health Action International’s (HAI) work in Europe aims at contributing to EU policy that promotes universal and equitable access to affordable medicines for needed treatment. HAI also supports policy and practice that ensures those medicines respond to societal challenges, are acceptably safe, appropriately prescribed and used. Through its European network, we bring independent patient and consumer voice in decisions that will affect their health whilst advocating for high levels of transparency, accountability and impartiality in all aspects of EU medicines policy. HAI’s European work plan 2016 is dedicated to identify, monitor and support EU policies that provide a response to persistent shortfalls in access to needed medicines and that are aligned with HAI’s overarching goals on Access to Needed Medicines, Rational Use of Medicines and Democratisation of Medicines Policy projects. HAI will work towards these goals through evidence-based policy analysis and intervention, training and information sharing. HAI’s work plan addresses the objectives of the Third Health Programme and contributes to EU added-value by supporting initiatives that have the potential to maximise the impact of policy intervention at a regional level, contributing to better and safer healthcare for all in Europe.
HAI is a non-profit, independent, NGO and maintains a European membership network of consumer groups, healthcare professionals, academics and public interest NGOs. The growing European regional network is represented in over half of European Union Member States. The HAI European office coordinates actions in collaboration with the HAI Europe Association and European civil society organisations.

Start date: 01/01/2016 - End date: 31/12/2016

Call: Health Programme Adhoc Call for invited (named) beneficiaries
Topic: Financial contributions to the functioning of non-governmental body (Operating grants)
3rd Health Programme (2014-2020)
HAI_FY2017 [HAI_FY2017]
Health Action International’s (HAI) work in Europe contributes to EU policy that promotes universal and equitable access to affordable medicines for needed treatment. HAI also supports policies and ...
Health Action International’s (HAI) work in Europe contributes to EU policy that promotes universal and equitable access to affordable medicines for needed treatment. HAI also supports policies and practices that ensure those medicines respond to societal challenges, are acceptably safe, and appropriately prescribed and used.
HAI’s 2017 European work plan focuses on providing technical expertise to policy makers, patient and consumer organisations, health NGOs and other relevant stakeholders. It also focuses on researching the extent of the pharmaceutical industry’s promotion of antibiotics to patients and healthcare professionals, as well as on identifying barriers to teaching on promotions in the medical curriculum. HAI will also enable public discussion on affordable access to needed medicines through the organization of public events. HAI will work towards these goals to support EU action that provides responses to gaps in medicines policies and are aligned with HAI’s overarching goals on Access to Needed Medicines, Rational Use of Medicines and Democratisation of Medicines Policy projects. Through its European network, HAI provides an independent patient and consumer voice in decisions that affects their health while advocating for high levels of transparency, accountability and impartiality.
HAI is a non-profit, independent non-profit organisation. It maintains a European membership network of consumer groups, healthcare professionals, academics and public interest NGOs. The growing European regional network is represented in over half of the EU’s Member States. The HAI European office coordinates actions in collaboration with the HAI Europe Association and European civil society organisations.

Start date: 01/01/2017 - End date: 31/12/2017

Call: Financial contribution to the functioning of non-governmental bodies (Operating grants)
Topic: Specific Grant Agreements under HP-FPA-2014
3rd Health Programme (2014-2020)
A Plan for Action: Ensuring Equitable, Affordable and Responsibly Used Medicines in the European Union [HAI_SGA2018]
Health Action International (HAI)'s European 2018 work plan builds on previous work supported by CHAFEA and aims to provide a response to persistent shortfalls in European medicines policy and regulat...
Health Action International (HAI)'s European 2018 work plan builds on previous work supported by CHAFEA and aims to provide a response to persistent shortfalls in European medicines policy and regulation. HAI’s work plan is aligned with the objectives of the Third Health Programme and with HAI’s organisational goals: (1) Access to Affordable Medicines, (2) Medicines Safety, Added Therapeutic Value and Responsible Use, (3) Democratisation of Medicines Policy.

HAI will keep on addressing those factors affecting access to medicines, including Intellectual Property rights while campaigning to broaden public and policy support to alternative models of biomedical innovation that contribute to medicines affordability and ensure public return on public investment. Advice and support will be provided to measures enhancing generic competition while bolstering governments position in procurement and medicines price negotiations.
As a member of the HTA Network Stakeholders Pool, HAI will contribute to the work of the network and issue recommendations to ensure that collaborative efforts strengthen the quality and robustness of HTA systems in Europe with the ultimate goal to enhance the sustainability of healthcare systems. Regarding the little (or non-existing) added therapeutic value of many new medicines, HAI will seek policy and regulatory support for more robust frameworks for medicines market approval; this will include initiatives for more proactive and robust pharmacovigilance systems to further protect patients’ safety. As a member of the European Medicines Agency (EMA) Patients’ and Consumers’ Working Party (PCWP), HAI will bring an independent consumers’ voice to EMA’s discussions and public consultations. We will closely follow developments in public access to clinical data in the EU and issue recommendations for enhanced transparency. In addition, we will implement initiatives to promote rational use of medicines by healthcare professionals.
Start date: 01/01/2018 - End date: 31/12/2018

Call: Financial contribution to the functioning of non-governmental bodies (Operating grants)
Topic: Specific Grant Agreements under HP-FPA-2017
3rd Health Programme (2014-2020)
A Plan for Action: Ensuring Equitable, Affordable and Responsibly Used Medicines in the European Union [SGA 2019 HAI]
Health Action International’s (HAI) 2019 European workplan builds on previous successes supported by CHAFEA. It provides a response to persistent shortcomings in European medicines policy and regula...
Health Action International’s (HAI) 2019 European workplan builds on previous successes supported by CHAFEA. It provides a response to persistent shortcomings in European medicines policy and regulation. HAI’s workplan is aligned with the objectives of the Third Health Programme and with HAI’s organisational goals: (1) Access to Affordable Medicines, (2) Medicines Safety, Added Therapeutic Value and Responsible Use, (3) Democratisation of Medicines Policy. In 2019, HAI will continue to address factors affecting access to medicines, including Intellectual Property Rights (IPR) while campaigning to broaden public and policy support in the European Union for alternative models of biomedical innovation that prioritise unmet medical needs, contribute to medicines affordability and ensure public return on public investment. Through the ‘Our Medicines, Our Right’ Campaign, we will seek to broaden policy support to medicines price transparency and R&D costs, as well as needs driven R&D modelling. We will roll-out campaign activities in Germany and thereby build bridges between policy discussions at the EU and Member State level. HAI will, furthermore, implement initiatives to promote responsible use of medicines, including antibiotics, by healthcare professionals. As a member of the Health Technology Assessment (HTA) Network Stakeholders Pool, HAI will contribute to the work programme of the network and advocate for strengthened EU collaboration on HTA. We will advocate specifically for joint HTA to be driven by high evaluation standards, transparency and independence from commercial interests. HAI will also seek policy and regulatory support for a more robust EU framework for medicines market authorization, in particular for cancer medicines. As a member of the European Medicines Agency (EMA) Patients’ and Consumers’ Working Party (PCWP), HAI will bring an independent consumers’ voice to EMA’s discussions and public consultations.
Start date: 01/01/2019 - End date: 31/12/2019

Call: Financial contribution to the functioning of non-governmental bodies (Operating grants)
Topic: Specific Grant Agreements 2019 under HP-FPA-2017
3rd Health Programme (2014-2020)
Health Action International proposal for a Specific Grant Agreement on operating costs for 2020 [SGA 2020 HAI]
Objectives: 1.Access to Affordable Medicines 2. Medicines Safety, Added Therapeutic Value and Responsible Use 3. Democratisation of Medicines Policy
Activities:
1: Seek policy support from the Govern...
Objectives: 1.Access to Affordable Medicines 2. Medicines Safety, Added Therapeutic Value and Responsible Use 3. Democratisation of Medicines Policy
Activities:
1: Seek policy support from the Governments of Member States for alternative models of biomedical innovation—delinking R&D costs from the final price of a given medicine—as one component of improving access to currently unaffordable medicines
2: Promote the use of public-health sensitive IP management tools and TRIPS flexibilities in the EU to secure affordable access to medicines and ensure the sustainability of health systems
3: Seek public and high-level government support for initiatives that improve public access to clinical trial data and data on risk biases, and that enhance medicines’ pricing and reimbursement policies that contribute to sustainable health systems
4: Advocate for improved marketing authorisation procedures
5: Continue to engage new cohorts of medical students on the need to respond critically to pharmaceutical promotion, expanding our influence to research facilities and teaching staff
6: Monitor, contribute and react to emerging and ongoing EU policy developments and issue communication and policy materials related to HAI’s areas of expertise
7: Facilitate knowledge exchange on HAI’s areas of expertise to civil society and to new MEPs through the dissemination of recommendations related to EU medicines policy, engagement in meetings and events
8: Strengthen the HAI Europe Association of members to ensure that civil society’s voice is well represented in medicines policy discussions
9: Ensure continuation and transparency of HAI’s work and expand donor relations
We expect to reach over 1000 policy-makers, civil society representatives and members of the research community in the EU through our online and in-person advocacy efforts in 2020. We will produce over 60 outputs in line with the 16 deliverables outlined in our proposal.
Start date: 01/01/2020 - End date: 31/12/2020

Call: Financial Contribution to the Functioning of Non-Governmental Bodies - Invitation to submit proposals for Specific Operating Grant Agreements (SGA)
Topic: Financial Contribution to the Functioning of Non-Governmental Bodies - Invitation to submit proposals for Specific Operating Grant Agreements (SGA)
3rd Health Programme (2014-2020)
A Plan for Action: Ensuring Equitable, Affordable and Responsibly Used Medicines in the European Union [HAI SGA 2021]
Health Action International’s work in Europe focuses on improving access to medicines through evidence-based advocacy, sharing expertise and engaging for change. To do this we campaign for greater t...
Health Action International’s work in Europe focuses on improving access to medicines through evidence-based advocacy, sharing expertise and engaging for change. To do this we campaign for greater transparency, and rationally used, affordable, safe and effective medicines.

PRIORITIES FOR 2021
European Parliament Working Group on Innovation, Access to Medicines and Poverty-related Diseases: HAI and MSF provide the secretariat for a group of European Parliamentarians interested in access to medicines issues. Over 2021 we will mobile this group to advocate on numerous issues.

Furthermore, we aim to change the narrative around TRIPS flexibilities to encourage more regular use of these legitimate tools. In 2021, we will implement the conclusions of the Great Health Hack, including producing the beta version of the technical solution suggested by participants. We hope to broaden understanding of the evidence base behind IP flexibilities and facilitate more policymakers to support implementation of a sustainable pricing system.

We will continue to share our recommendations how Member States can achieve greater transparency in medicines prices, research and development (R&D) costs and reimbursement decisions.

We will facilitate medical students and healthcare professionals to detect, counter and avoid exposure to pharmaceutical promotion.

As always, there will be many other upcoming issues and opportunities in access to medicines this year, both regionally and globally. We will be watching how other dossiers and events unfold in the fight against medicine shortages, also in light of COVID-19.

We pride ourselves on being active members of European civil society and part of the global access to medicines movement, via groups like the European Alliance for Responsible R&D and Affordable Medicines, Medicijnen Netwerk Nederland, HTA Network Stakeholder Pool and the EMA PCWP.

Start date: 01/01/2021 - End date: 31/12/2021

Call: Invitation to submit proposals for Specific Operating Grants (SGA) for the year 2021 under the Annual Work Programme 2020 of 3HP
Topic: Specific Operating Grants for the year 2021
3rd Health Programme (2014-2020)
A Plan for Action: Ensuring Equitable, Affordable and Responsibly Used Medicines in the European Union [HAI_FPA2018]
Stichting (Foundation) Health Action International's European multi-annual programme 2018-2021 builds on previous work supported by CHAFEA and aims to provide a response to persistent shortfalls in Eu...
Stichting (Foundation) Health Action International's European multi-annual programme 2018-2021 builds on previous work supported by CHAFEA and aims to provide a response to persistent shortfalls in European medicines policy. HAI’s work plan is aligned with the objectives of the Third Health Programme and with HAI’s organisational goals: (1) Access to Affordable Medicines, (2) Medicines Safety, Added Therapeutic Value and Responsible Use, (3) Democratisation of Medicines Policy.

In particular, HAI will campaign to broaden public and policy support to alternative models of biomedical innovation that contribute to medicines affordability and ensure public return on public investment. We will also provide advice and support initiatives that enhance generic competition and empower governments in medicines price negotiations. As a member of the HTA Network Stakeholders Pool for the mandate 2016-2020, HAI will contribute to the work of Stakeholders Pool and issue recommendations to ensure that collaborative efforts strengthen the quality and robustness HTA systems in Europe with the ultimate goal to enhance the sustainability of healthcare systems and medical innovation. Following concerns about the little (or non-existing) added therapeutic value of many new medicines, HAI will seek policy and regulatory support for more robust frameworks for medicines. We will support initiatives for more proactive and robust pharmacovigilance systems to further protect patients’ safety. As a member of the European Medicines Agency (EMA) Patients’ and Consumers’ Working Party (PCWP), HAI will bring independent consumers’ voice to EMA’s policies and initiatives. We will follow closely developments on public access to clinical data in the EU and issue recommendations for enhanced transparency. In addition, we will implement initiatives for enhanced rational use of medicines for example by capacitating healthcare professionals to better assess information on medicines.
Start date: 09/03/2018 - End date: 08/03/2022

Call: Operating grants 2018-2021
Topic: Financial contribution to the functioning of non-governmental bodies
3rd Health Programme (2014-2020)
Health Action International (HAI) Europe Multi-annual Programme 2015-2017: Equitable access to medicines, their rational use and good governance in the European Union [HAI_FY2015]
HAI Europe contributes to European Union (EU) policy that promotes universal and equitable access to affordable needed medicines of assured quality and policy and practice that ensures those medicines...
HAI Europe contributes to European Union (EU) policy that promotes universal and equitable access to affordable needed medicines of assured quality and policy and practice that ensures those medicines are used rationally. HAI Europe’s work plan 2015-2017 is dedicated to identify, monitor and support EU policies that provide a response to persistent shortfalls in access to medicines and that are aligned with HAI’s overarching goals on Access to Needed Medicines, Rational Use of Medicines and Democratisation of Medicines Policy in Europe. HAI will work towards these goals through research, evidence-based policy analysis and intervention, training and information sharing. As a result, HAI will advocate for citizen-centred public health policies that address health challenges in the EU and health inequity both within and between EU member states. HAI Europe’s multi-annual programme addresses the objectives of the Third Health Programme and contributes to EU added-value by supporting medicines policies that have the potential to maximise the impact of policy intervention at a regional level, and thereby contributes to better and safer healthcare for EU citizens. HAI Europe is a non-profit, independent NGO and maintains a membership network of consumers, healthcare providers, academics and public interest groups working on pharmaceutical policy issues in Europe. The growing European regional network is represented in over half of EU Member States. The HAI Europe office coordinates actions with the HAI Europe Members Association, and integrates its work in collaboration with other European civil society organisations.
Start date: 17/12/2014 - End date: 16/12/2017

Call: Call for Proposals for Framework Partnership Agreement for Operating Grants 2014
Topic: Financial contribution to the functioning of non-governmental body (Framework Partnership Agreements 2015-2017)